Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
eken m001 google android tablet is here
Popular Articles

Researchers Make Progress Toward Early Identification Of Muscular Dystrophy
The saying "Knowing is half the battle" is never more true than when discussing early treatment of disease. Muscular dystrophy is one such disease where patients can benefit from early treatment. Now, new research is moving doctors and scientists closer to disease diagnosis in advance of patient symptoms.
generic viagra online
New York Times Examines Program To Help Orphans Survive 'Fragile Days Of Infancy'
The New York Times examines a program being offered at an orphanage in Tanzania that provides emotional and physical support for newborns and young children who are at a high risk of death after losing their mothers in infancy. "Africa is full of at least 50 million orphans, the legacy of AIDS and other diseases, war and high rates of death in pregnancy and childbirth," the newspaper writes. "With the numbers increasing every day, Africans are struggling to care for them, often in ways that differ strikingly from the traditional concept of an orphanage in the developed world."
News of the day
Brain Energy Use Key To Understanding Consciousness, Yale Researchers Find
High levels of brain energy are required to maintain consciousness, a finding which suggests a new way to understand the properties of this still mysterious state of being, Yale University researchers report.
Diagnostics

Eurand Successfully Completes Registration Procedure For Paracetamol ODT 250 And 500 Mg In The European Union

Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced that the Dutch Medicines Evaluation Board (MEB) informed the Company that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500 mg Orodispersible Tablets (ODT) in several EU countries has been successfully completed. In addition to The Netherlands, which acted as the reference member state, the DCP involved the United Kingdom, Germany, France, Italy and Spain. Formal approval is now expected from each country by the end of 2009. Eurand is actively seeking a partner to market and distribute Paracetamol ODT in these countries. Paracetamol (also known as acetaminophen) is a widely used analgesic (pain reliever) and antipyretic (fever reducer). Paracetamol ODT is indicated for symptomatic treatment of mild-to-moderate pain and/or fever. The 500 mg dose is indicated in adults and adolescents (over 12 years old) only, and the 250 mg dose is for use in children from the age of four and adolescents only. The product may be taken with or without liquid. "We are pleased by the Dutch MEB"s decision regarding our Paracetamol ODT, and we look forward to receiving approval in the six individual countries later this year," said GearÃöid Faherty, Chairman and Chief Executive Officer. "We believe our formulation will deliver this well-recognized pain reliever in a more patient friendly manner, particularly for those patients who have difficulty swallowing." He noted that this is the second ODT formulation that Eurand has had approved this year. In May 2009, the FDA approved EUR-1048, marketed by GlaxoSmithKline as Lamictal® ODT™ (lamotrigine) Orally Disintegrating Tablets. Like Paracetamol ODT, Lamictal ODT uses Eurand"s AdvaTab® orally disintegrating tablet (ODT) and Microcaps® taste-masking technologies. Eurand


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009